Only 20% of NKX2-1-positive tumors were diffusely positive (vs. 41% of mucinous tumors), and 35% of NKX2-1-positive tumors were negative for pERK (vs. 18% of mucinous tumors). Here, NKX2-1 is linked to mucinous neoplasm.